Fate Therapeutics, Inc. FATE

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

• GlobeNewswire Inc. 1 oct

  Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

  Fate Therapeutics announced that management will participate in two major investor conferences in Q4 2026: the Jefferies Global Healthcare Conference in London (November 16-19) and the Piper Sandler 38th Annual Healthcare Conference in New York (December 1-3). Live webcasts will be available on the company's investor website.

  

• GlobeNewswire Inc. 16 sept

  Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

  Fate Therapeutics announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at ACR Convergence 2026. The presentations will showcase clinical data for FT819, including administration without conditioning chemotherapy and outpatient administration capabilities, as well as updates on the Phase 1/2 COMPLETE Trial for FT839, a dual-CAR T-cell candidate targeting CD19 and CD38 for autoimmune diseases.

  

• GlobeNewswire Inc. 14 sept

  Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight

  The lupus nephritis market is projected to grow at a 7% CAGR through 2036, driven by increasing disease awareness, improved diagnosis, and expanding adoption of targeted therapies. The market was valued at USD 2.1 billion in 2025 across seven major markets. Three therapies have received FDA approval (belimumab, voclosporin, and obinutuzumab), while a robust pipeline of innovative treatments including CAR-T therapies, complement inhibitors, and monoclonal antibodies is expected to transform disease management.

  

• GlobeNewswire Inc. 10 jun

  Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight

  The lupus nephritis drug development pipeline is rapidly expanding with 30+ pharmaceutical companies developing 35+ pipeline therapies across various clinical stages. Key players including Novartis, Simcere Pharmaceutical, Kyverna Therapeutics, Century Therapeutics, and Adicet Bio are advancing promising treatments with novel mechanisms of action such as BAFF-R inhibitors, CAR-NK cell therapies, and anti-CD19/CD20 approaches. Recent regulatory milestones include FDA RMAT designations for cell therapies and positive Phase III trial results, indicating accelerating progress in addressing this serious autoimmune kidney disease.